Latest news

RegulatorySeptember 3, 2026

FDA Approves Eli Lilly’s Mounjaro to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major...

CommercialSeptember 3, 2026

Roche’s Genentech Partners With DualityBio on ADCs Designed to Address Cancer Drug Resistance

Roche’s Genentech has entered into a collaboration and licensing agreement with Shanghai-based DualityBio to develop antibody-drug conjugates (ADCs) intended...

InsightsSeptember 3, 2026

Top 10 Technologies Improving Market Access in Pharma

Executive Summary Market access has become increasingly complex as pharmaceutical companies navigate evolving reimbursement models, rising evidence requirements, pricing pressure,...

InsightsSeptember 3, 2026

Top 10 Innovations in Target Identification in Drug Development

Executive Summary Target identification is one of the most consequential stages of drug development. Selecting the right biological target can...

CommercialSeptember 3, 2026

Novartis and Alteogen sign a $3.2 billion subcutaneous medication delivery agreement

With South Korea's Alteogen, Novartis has secured access to...

InsightsSeptember 3, 2026

Top 10 Data Governance Priorities for Life Sciences Leaders

Executive Summary Data has become one of the most important...

InsightsSeptember 3, 2026

Agentic AI in Life Sciences

Executive Summary Artificial intelligence in life sciences is moving beyond systems that simply generate answers or analyze information. The next stage...

ClinicalSeptember 2, 2026

Novartis Reports Positive Phase 3 Results for Rhapsido in Relapsing Multiple Sclerosis

Novartis has reported positive results from two phase 3 clinical trials evaluating Rhapsido (remibrutinib) in relapsing multiple sclerosis (MS),...

ManufacturingSeptember 2, 2026

ArsenalBio Lays Off 99 Employees and Shifts Focus to In Vivo CAR-T Programs

Arsenal Biosciences (ArsenalBio) is reducing its workforce by 99 employees as part of a strategic transition toward the development...

RegulatoryAugust 31, 2026

FDA Clears Jazz’s Ziihera for First-Line Treatment of HER2-Positive Gastroesophageal Cancer

Jazz’s ;The U.S. Food and Drug Administration has approved...

InsightsAugust 31, 2026

Why AI Agents Will Become Every Pharmaceutical Employee’s Copilot

Executive Summary Artificial intelligence is moving from a technology employees...

InsightsAugust 31, 2026

How Digital Twins Are Transforming Drug Development

Executive Summary Drug development is becoming increasingly data-driven, computational, and personalized. Yet pharmaceutical companies still rely heavily on physical experiments...

RegulatoryAugust 31, 2026

FDA Extends Review of Capricor’s Deramiocel for Duchenne Muscular Dystrophy to November

The U.S. Food and Drug Administration (FDA) has extended its review of Capricor Therapeutics’ investigational cell therapy deramiocel for...

ClinicalAugust 31, 2026

Ambros and Werewolf Merge as Neridronate Advances in Phase 3 Trial for CRPS-1

Ambros Therapeutics and Werewolf Therapeutics have entered into an all-stock merger agreement alongside a concurrent $150 million private placement....